Tag: biopharma
-
JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth
Overview: A Scaled CRDMO Engine for Sustainable Growth Under the leadership of Dr. Chris Chen, WuXi Biologics has expanded its contract development and manufacturing organization (CRDMO) platform to deliver sustainable, high-growth results. The company reports a robust year for 2025, driven by a diversified mix of projects across complex modalities and stages of development. This…
-
Insmed to Present at the 44th Annual JP Morgan Healthcare Conference: What Investors Should Expect
Insmed to Present at the 44th Annual JP Morgan Healthcare Conference Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company, announced its plan to present at the 44th Annual JP Morgan Healthcare Conference. The conference, widely considered a bellwether event for the biopharma sector, will gather investors, analysts, and industry leaders to hear the latest…
-
All In on Biosim AI with Simulations Plus: A TD Cowen Insights Discussion
Introduction: A New Frontier in Biosim AI The latest TD Cowen Insights episode dives into the convergence of biology and artificial intelligence, spotlighting how biosimulation experts are reshaping the development of biosimilars. With Simulations Plus at the helm, the discussion unpacks how AI-powered simulations can streamline drug development, improve predictability, and reduce costs. This episode…
-
NICE Recommends AUCATZYL (obecabtagene autoleucel) for UK patients
Summary: NICE backs AUCATZYL for eligible patients The National Institute for Health and Care Excellence (NICE) has recommended AUCATZYL, the CAR-T cell therapy obatabtagene autoleucel (also known as obecabtagene autoleucel), for use within the UK’s healthcare system. The decision marks a significant milestone for patients with certain hematologic cancers and highlights the growing role of…
-
MIT Engineers Unstick Cells on Demand With Bubble-Driven Detachment in Bioreactors
Revolutionizing cell adhesion in bioreactors and beyond MIT researchers have unveiled a scalable, high-throughput method to detach cells from surfaces on demand using electrochemically generated bubbles. Published in Science Advances, the approach could dramatically reduce downtime and waste across industries that rely on cell cultures, including algae bioreactors for carbon capture, pharmaceutical manufacturing, biofuels, biosensors,…
-
MIT Engineers Solve Sticky-cell Problem In Bioreactors And Other Industries
Introduction: A Simple Problem, Big Impact Bioreactors and related processes across industries—from algae farming in climate-friendly carbon capture efforts to manufacturing biologic drugs—face a stubborn obstacle: cells sticking to surfaces. This adhesion reduces light exposure in photobioreactors, clogs harvesting lines, and forces costly downtime for cleaning and sanitation. MIT researchers have now introduced a high-throughput,…